TDO-IN-2

• Description:

  TDO-IN-2 (Compound 5c) is an orally active TDO inhibitor (IC50: 1.25 μM) . TDO-IN-2 has antitumor activity in the Hepa1-6 hepatocellular carcinoma allograft mouse model. TDO-IN-2 has synergistic effects with the PD-1/PD-L1 inhibitor BMS-202 (HY-19745) and can be used to study tumor immune tolerance[1].

• UNSPSC:

  12352211

• Target:

  Indoleamine 2,3-Dioxygenase (IDO)

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  O=C (/C (C#N) =C/C1=CNC2=CC=CC=C12) NC3=CC (OCCO4) =C4C=C3

• Molecular Formula:

  C20H15N3O3

• Molecular Weight:

  345.35

• References & Citations:

  [1]Wang X, et al. Discovery of (E) -2-cyano-N- (2,3-dihydrobenzo[b][1,4] dioxin-6-yl) -3- (1H-indol-3-yl) acrylamide as a novel TDO inhibitor for cancer treatment. Bioorg Chem. 2025 May 5;161:108555.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported